Skip to main content
Article
Oral contraceptive formulation and risk of breast cancer.
Contraception
  • Polly A. Marchbanks, Centers for Disease Control, Atlanta, Georgia
  • Katheryn M. Curtis, Centers for Disease Control, Atlanta, Georgia
  • Michele G. Mandel, Centers for Disease Control, Atlanta, Georgia
  • Hoyt G. Wilson, Centers for Disease Control, Atlanta, Georgia
  • Gary Jeng, Centers for Disease Control, Atlanta, Georgia
  • Suzanne G. Folger, Centers for Disease Control, Atlanta, Georgia
  • Jill A. McDonald, Centers for Disease Control, Atlanta, Georgia
  • Janet R. Daling, Fred Hutchinson Cancer Research Center
  • Leslie J. Bernstein, Beckman Research Institute, City of Hope, Duarte, CA
  • Kathleen E. Malone, Fred Hutchinson Cancer Research Center
  • Phyllis A. Wingo, Centers for Disease Control, Atlanta, Georgia
  • Michael S. Simon, Wayne State University
  • Sandra A. Norman, University of Pennsylvania
  • Brian L. Strom, University of Pennsylvania
  • Giske A. Ursin, Cancer Registry of Norway, Oslo, Norway
  • Linda K. Weiss, National Institute of Health
  • Ronald T. Burkman, Tufts University School of Medicine
  • Robert Spirtas, George Washington University
Document Type
Journal Article
Publication Date
4-1-2012
Inclusive Pages
342-350
Keywords
  • Breast Neoplasms--chemically induced,
  • Contraceptives,
  • Oral--adverse effects,
  • Contraceptives,
  • Oral,
  • Hormonal--adverse effects
Comments

This is an open access PubMed Central article. Click on link for full-text access.

Peer Reviewed
1
Open Access
1
Citation Information
Polly A. Marchbanks, Katheryn M. Curtis, Michele G. Mandel, Hoyt G. Wilson, et al.. "Oral contraceptive formulation and risk of breast cancer." Contraception Vol. Volume 85, Issue 4 (2012)
Available at: http://works.bepress.com/ronald_burkman/16/